TELESTA THERAPEUTICS INC T.TST

When even the analysts call BS, you know something is off...

[cndexpatman]

When even the analysts, who clearly understand the story, think something is off with this NO vote, you know there is much more at play here...

Analyst hits nail on head

No denying that the No vote was decisive, but frequently with positive commentary on its prospects,” says the analyst. “We are quite prepared to take our lumps on negative clinical and/or regulatory events for technology developers in our coverage universe (and we have!), but to be blunt, some of the criticisms of MCNA by the No voters were just baffling to us, and with impractical consequences. First of all, the post-vote explanations from the No voters were frequently quite positive on MCNA’s medical utility (huh?), and there was clearly no guidance from Panel administrators on the incongruity of these two lines of thought.

We heard the phrase that MCNA ‘sure would be nice to have’ more than once during the day. Secondly, more than one panelist effectively criticized MCNA for having a benign safety profile (again, huh?), citing this as a reason why MCNA could discourage other new therapies from being tested in BCG-refractory disease, maybe on the concern that future drugs would be compared more to MCNA’s safety than to its efficacy. We have just never heard of this as a concern for any developmental therapy we have reviewed.”

In a research update to clients today, Loe downgraded Telesta Therapeutics from “Speculative Buy” to “Hold” and cut his one-year price target from $1.70 to $0.30, implying a return of 24.1 per cent at the time of publication.

[DamnYankees]

I think that today would be a good to be a Euro Pacific client. That was the ultra Conservative party line and it was provocative, given the magnitude and drakes involved. Would like to see the entirety of his thought process. I am willing to bet he knows that this is a long way from over. You might even see some elaboration on the possible lines of recourse moving forward.